Lumisys reports flat revenues, although trend shows improvement

Article

A continuing slump in film digitizer sales impacted third-quarter earnings for film digitizer firm Lumisys. Although sales did show signs of rebounding, the Sunnyvale, CA, company reported 2% revenue growth in its third quarter compared with the same

A continuing slump in film digitizer sales impacted third-quarter earnings for film digitizer firm Lumisys. Although sales did show signs of rebounding, the Sunnyvale, CA, company reported 2% revenue growth in its third quarter compared with the same period in 1996. Meanwhile, efforts to broaden the company's product offerings are continuing.

For its third quarter (end-September), Lumisys posted revenues of $6 million, compared with $5.9 million in 1996. Net income was $616,000, compared with $817,000 for the same period last year.

In positive news for Lumisys, backlog increased 47% to $4.6 million, a record high. In addition, the company has $1.3 million in equipment orders that are not included in the backlog figure, in which the company only includes orders up to six months ahead. Revenues also grew 14% compared with the second quarter.

While company officials believe the digitizer market to be in a growth phase again, they have taken steps to diversify the company's product offerings. In addition to the planned acquisition of PACS and teleradiology software supplier CompuRad (SCAN 10/1/97), Lumisys announced in April that it was developing a low-cost computed radiography reader for the medical market.

After the acquisition of CompuRad is finalized, some of that vendor's engineers will be working on the CR project. Tucson, AZ-based CompuRad will contribute a large portion of the graphical user interface as well as network transmission software to the project. The CR reader is on track to reach the market in late 1999, said Stephen Weiss, president and CEO.

Lumisys has also begun responding to the class-action lawsuit that was filed against the vendor in July by a group of shareholders upset with a decline in the firm's stock. The company filed a motion to dismiss the case in federal court on Sept. 21. A hearing on the motion is scheduled in December, with a response expected by January, Klosterman said. Lumisys also planned to file a similar motion in state court on Oct. 10.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.